173 related articles for article (PubMed ID: 9477183)
21. The BTA stat test: a tumor marker for the detection of upper tract transitional cell carcinoma.
Walsh IK; Keane PF; Ishak LM; Flessland KA
Urology; 2001 Oct; 58(4):532-5. PubMed ID: 11597532
[TBL] [Abstract][Full Text] [Related]
22. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patients with recurrent bladder tumors. The Multi Center Study Group.
Ellis WJ; Blumenstein BA; Ishak LM; Enfield DL
Urology; 1997 Dec; 50(6):882-7. PubMed ID: 9426718
[TBL] [Abstract][Full Text] [Related]
23. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
[TBL] [Abstract][Full Text] [Related]
24. Predictive values of urinary bladder tumor markers survivin and soluble-Fas comparison with cystoscopy and bladder tumor antigen.
Ganas V; Kalaitzis C; Sountoulides P; Giannakopoulos S; Touloupidis S
Minerva Urol Nefrol; 2012 Dec; 64(4):279-85. PubMed ID: 23288215
[TBL] [Abstract][Full Text] [Related]
25. The dilemma of suspicious urine cytology in patients being followed for bladder cancer.
Raitanen MP; Aine R; Kylmälä T; Kallio J; Liukkonen T; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):256-9. PubMed ID: 11820413
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
Leyh H; Hall R; Mazeman E; Blumenstein BA
Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018
[TBL] [Abstract][Full Text] [Related]
27. Performance characteristics of multiple urinary tumor markers and sample collection techniques in the detection of transitional cell carcinoma of the bladder.
Bhuiyan J; Akhter J; O'Kane DJ
Clin Chim Acta; 2003 May; 331(1-2):69-77. PubMed ID: 12691866
[TBL] [Abstract][Full Text] [Related]
28. [The BTA stat test in the follow-up for bladder cancer].
Gutiérrez Baños JL; Martín García B; de Diego Rodríguez E; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; Rado Velázquez MA
Arch Esp Urol; 1999 Oct; 52(8):856-61. PubMed ID: 10589117
[TBL] [Abstract][Full Text] [Related]
29. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine.
Halling KC; King W; Sokolova IA; Karnes RJ; Meyer RG; Powell EL; Sebo TJ; Cheville JC; Clayton AC; Krajnik KL; Ebert TA; Nelson RE; Burkhardt HM; Ramakumar S; Stewart CS; Pankratz VS; Lieber MM; Blute ML; Zincke H; Seelig SA; Jenkins RB; O'Kane DJ
J Urol; 2002 May; 167(5):2001-6. PubMed ID: 11956427
[TBL] [Abstract][Full Text] [Related]
30. BTA quantitative assay and NMP22 testing compared with urine cytology in the detection of transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Zitella A; Pelucelli G; Formiconi A; Priolo G; Martinasso G; Mengozzi G; Aimo G; Viberti L; Tizzani A
Urol Int; 2000; 65(2):100-5. PubMed ID: 11025432
[TBL] [Abstract][Full Text] [Related]
31. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Egarter Vigl E; Marberger M; Pycha A
Urology; 2000 Aug; 56(2):228-31. PubMed ID: 10925083
[TBL] [Abstract][Full Text] [Related]
32. BTA TRAK urine test increases the efficacy of cytology in the diagnosis of low-grade transitional cell carcinoma of the bladder.
Gibanel R; Ribal MJ; Filella X; Ballesta AM; Molina R; Alcaraz A; Alcover JB
Anticancer Res; 2002; 22(2B):1157-60. PubMed ID: 12168917
[TBL] [Abstract][Full Text] [Related]
33. Comparison of BTA stat and NMP22 tests in the detection of bladder cancer.
Oge O; Atsü N; Sahin A; Ozen H
Scand J Urol Nephrol; 2000 Dec; 34(6):349-51. PubMed ID: 11195897
[TBL] [Abstract][Full Text] [Related]
34. BTA-TRAK combined with urinary cytology is a reliable urinary indicator of recurrent transitional cell carcinoma (TCC) of the bladder.
Mattioli S; Seregni E; Caperna L; Botti C; Savelli G; Bombardieri E
Int J Biol Markers; 2000; 15(3):219-25. PubMed ID: 11012097
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of DD23 as a marker for detection of recurrent transitional cell carcinoma of the bladder in patients with a history of bladder cancer.
Gilbert SM; Veltri RW; Sawczuk A; Shabsigh A; Knowles DR; Bright S; O'Dowd GJ; Olsson CA; Benson MC; Sawczuk IS
Urology; 2003 Mar; 61(3):539-43. PubMed ID: 12639642
[TBL] [Abstract][Full Text] [Related]
36. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
37. The role of BTA stat in clinical practice.
Quek P; Chin CM; Lim PH
Ann Acad Med Singap; 2002 Mar; 31(2):212-6. PubMed ID: 11957560
[TBL] [Abstract][Full Text] [Related]
38. A study comparing various noninvasive methods of detecting bladder cancer in urine.
Saad A; Hanbury DC; McNicholas TA; Boustead GB; Morgan S; Woodman AC
BJU Int; 2002 Mar; 89(4):369-73. PubMed ID: 11872026
[TBL] [Abstract][Full Text] [Related]
39. Routine follow-up cystoscopy in detection of recurrence in patients being monitored for bladder cancer.
Raitanen MP; Leppilahti M; Tuhkanen K; Forssel T; Nylund P; Tammela T;
Ann Chir Gynaecol; 2001; 90(4):261-5. PubMed ID: 11820414
[TBL] [Abstract][Full Text] [Related]
40. NMP 22, BTA stat test and cytology in the diagnosis of bladder cancer: a comparative study.
Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juárez FM; Martín García B
Urol Int; 2001; 66(4):185-90. PubMed ID: 11385303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
